

R. B. Gohil & Co. Chartered Accountants

LIMITED REVIEW REPORT ON UNAUDITED HALF YEARLY FINANCIAL RESULTS OF COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

To the Board of Directors of Global Longlife Hospital and Research Limited

We have reviewed the accompanying statement of unaudited financial results of Global Longlife Hospital and Research Limited for the period ended 30th September, 2025. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, M/s. R B Gohil & Co. Chartered Accountants FRN No. 119360W

Place: Jamnagar

Date: 12th November, 2025

CA Raghubha B. Gohil

Partner

M.No. 104997

UDIN: 25104997BMGFRL5249



GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED

CIN: L85110GJ2012PLC068700

REGD OFFICE: 703, SANKALP SQUARE 3B, BESIDE TAJ SKYLINE, SINDHU BHAVAN ROAD, THALTEJ, AHMEDABAD, 380059

UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED ON 30.09.2025

		1	Ialf Year Ended	(****	ı Lakhs except p Year E	
Sr.		30.09.2025	31.03.2025	30.09.2024	31.03.2025	31.03.2024
No.	Particulars	Unaudited	Audited	Unaudited	Audited	Audited
		Unaudited	Audited	Chaudited	rudited	
		-	0.00	57.73	57.73	1,351.45
	Revenue from Operations	0.52	(67.36)	568.97	501.61	6.33
	Other Income	0.52	(67.36)	626.70	559.34	1,357.78
1	Total Income	0.52	(67.36)	020.70	337.34	1,557770
2	Expenses		66.64	116.01	182.65	724.45
	Direct Expenses	-	00.04	110.01	102.03	84.20
	Purchase of Stock-in-Trade	-	- 0.00	43.72	43.72	37.83
	Changes in inventories of finished goods and stock in trade	- 10.73	0.00	43.72	113.58	333.69
	Employee benefits expenses	18.72	70.50	27.56	27.62	76.83
	Finance Costs	0.01	0.06		48.19	* 125.01
	Depreciation and amortisation expenses	-	(0.19)	48.38		202.36
	Other Expenses	40.98	(103.01)	236.67	133.66	
	Total Expenses	59.71	34.00	515.42	549.42	1,584.37
3	Profit/(Loss) before exceptional and extrordinary items and tax (1 - 2)	(59.19)	(101.36)	111.28	9.92	(226.59)
4	Exceptional Items	-	-	-	- 0.02	(226.50)
5	Profit/(Loss) before extraordinary item and tax (3 - 4)	(59.19)	(101.36)	111.28	9.92	(226.59)
6	Extraordinary Items	-	-	-		(224.50)
7	Profit/(Loss) before tax (5 - 6)	(59.19)	(101.36)	111.28	9.92	(226.59)
8	Tax Expense					
	a) Current tax	11. H	2.58	-	2.58	-
	b) Deferred tax		0.05	(12.58)	(12.53)	(7.78
	c) Excess/(Short) Provision Of Earlier Years	73.15	-	-		
9	Net Profit/(Loss) from continuing activities after tax (7 - 8)	(132.34)	(103.99)	123.86	19.87	(218.81
10	Net Profit/(Loss) from discontinued operations before tax	-		-	-	-
11	Tax Expense of discontinued operations	-	•	-	-	-
12		7	-	-	-	-
13		(132.34)	(103.99)	123.86	19.87	(218.81
14						
	a) Items that will not be reclassified to profit or loss	-	<u> </u>	8#		
	b) Income tax relating to items that will not be reclassified to profit or loss	97	-	-	-	2
	Total					
15		(132.34)	(103.99)	123.86	19.87	(218.81
16						-
-	Paid-up Equity Share Capital	1,050.00	1,050.00	1,050.00	1,050.00	1,050.00
	Face Value of Equity Share Capital	10.00	10.00	10.00	10.00	10.00
17					1,628.88	1,543.14
18	Basic earning (loss) per share from continuing and discountinued	(1.26)	(0.99)	1.18	0.19	(2.08
	operation	(1.26)	(0.99)	1,16	0.19	(2.00
19	Diluted earning (loss) per share from continuing and discountinued	71.27	(0.99)	1.18	0.19	(2.08
	operation (1997)	(1.26)	(0.99)	1,10	0.19	
	Debt Equity Ratio	1	-	п.	-	0.49
	Debt Service Coverage Ratio	F.75	-	0.43	0.17	(2.24
-	Interest Service Coverage Ratio	141	-	28.04	10.84	(4.83

For, Global Longlife Hospital and Research Limited

Dhru Jan AHMEDABAD Managing Director

DIN: 03154680

Date: 12th November, 2025 Place: Ahmedabad

GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED

Regd. Office: 703, Sankalp Square, 3B, Beside Taj Skyline, Sindhu Bhavan Road, Ahmedabad – 380 059, Gujarat, India CIN: L85110GJ2012PLC068700, Tel No.: (+91) 7211104280; Email:

info@globalhospital.co.in: Website: www.globalhospital.co.in



A division of ।। सर्वे सन्तु निरामयाः ।। Global Longlife Hospital & Research Ltd. GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED

CIN: L85110GJ2012PLC068700

REGD OFFICE: 703, SANKALP SQUARE 3B, BESIDE TAJ SKYLINE, SINDHU BHAVAN ROAD, THALTEJ, AHMEDABAD, 380059

			(Rs. In Lakhs
	Descion Less	As At 30.09.2025	As At 31.03.2025
	Particulars	Unaudited	Audited
	Equity and liabilities		
1	Shareholders' funds	1,050.00	1,050.00
	Share capital	1,496.54	1,628.88
	Reserves and surplus	1,490.34	1,020.00
	Money received against share warrants Total shareholders' funds	2,546.54	2,678.8
2	Share application money pending allotment	-	-
3	Deferred government grants	-	-
4	Minority interest		-
5	Non-Current Liabilities		
5	Long-term borrowings	-	-
	Deferred tax liabilities (net)	-	-
	Other long-term liabilities	-	1=
	Long-term provisions	-	
	Total Non-Current Liabilities	_	
6	Current Liablities		
0		-	
	Short-term borrowings Trade Payables		
	(A) Total outstanding dues of micro enterprises and small		- mile and the second s
	enterprises.	-	
	(B) Total outstanding dues of creditors other than micro		
	enterprises and small enterprises.	0.16	
	Other current liabilities	0.18	1.2
	Short-term provisions	1.00	4.3
	Total current liabilities	1.34	5.:
	Total equity and liabilities	2,547.88	2,684.
			•
	Assets		
1	Non-current assets		
(i)	Fixed assets	_	
	Tangible assets		
	Producing properties	-	
	Intangible assets	-	
	Preproducing properties	-	
	Tangible assets capital work-in-progress		
	Intangible assets under development or work-in-progress		
	Total fixed assets	-	
	ILOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED		



lobal Le	englife Hospital & Research Ltd.		
4			
(ii)	Non-current investments	-	3.00
(iii)	Deferred tax assets (net)	234.78	234.78
(iv)	Long-term loans and advances	,	-
(v)	Other non-current assets	147.46	182.95
	Total non-current assets	382.24	420.73
2	Current assets		
	Inventories	-	-
	Trade receivables	29.26	32.12
	Cash and cash equivalents	2,107.97	2,149.18
	Short-term loans and advances	0.63	26.36
	Other current assets	27.79	56.07
	Total current assets	2,165.64	2,263.73
	Total assets	2,547.88	2,684.46

For, Global Longlife Hospital and Research Limited

BOBAKO BA AHMEDABAD Dhruy Jani

Managing Director

DIN: 03154680

Date: 12th November, 2025

Place: Ahmedabad

AHMEDABAD, 380059

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED ON 30.09.2025

	Particulars	30-09-2025 Unaudited	30-09-2024 Unaudited	31-03-2025 Audited
-				
A. CASI	H FLOW FROM OPERATING ACTIVITIES			
	Profit before taxation and extraordinery items	(59.19)	111.28	9.92
	stment for :-			
Depre	eciation and Amortization	-	48.38	48.19
Non-	cash items	-	-	67.79
Sale	of Fixed Asset	-	-	(431.18
Net L	.oss/(Gain) on Sale of Investments	-	-	(57.12
Chan	ge in Reserve & Surplus	-		65.86
Finan	nce Costs	0.01	27.56	27.62
		(59.18)	187.21	(268.91
Oper	rating Profit berfore working capital changes			
Chan	nge in working Capital :			
Adju	stment for Decrease (Increase) in operating assets			
Inven	ntories	-	43.72	43.72
Trade	e receivables	2.86	64.95	162.48
Other	r Current Assets & Loans Advances	54.02	(26.55)	-
Other	r Non current Asset	35.49	1,639.68	1,637.43
	stment for (Decrease) Increase in opearting liabilities			
Trade	e payables	0.16	(254.23)	(255.8)
Other	r current liabilities	(1.02)	(31.49)	(42.39
Other	r Provision	(3.38)	(0.90)	(4.9
Cash	Generated from Operations			
Direc	et tax Paid			26.3
Divid	dends received	(0.45)	(0.45)	(0.4
Intere	est received	(0.07)	(4.12)	(12.5)
Cash	(Used in)/Generated from Operations	28.43	1,617.82	1,232.0
Tax	Paid (Net)	73.15	-	(¥)
Net c	eash from Operating Activities	(44.72)	1,617.82	1,232.0
P NET	CASH FLOW FROM INVESTMENT ACTIVITIES			
	hase of Fixed Assets			
	hase of Property, Plant and Equipment			(7.2-
	eeds from Sale of Equity Instruments	3.00		(7.2
	eeds from sales of property, plant and equipment	5.00	1,678.62	2,117.2
_	hase of Mutual Funds		1,070.02	(1,850.0
2 300	eeds from Sale / Redmption of Mutual Funds			1,907.1
_	s and Advances given			1,707.1
-	dends received	0.45	0.45	0.4
-	est received	0.43	4.12	12.5
	eeds from maturity of term deposits	0.07	7.12	1 20.0
			(1,863.50)	
	stment in Securities		(1,803.30)	(0.2
	stment in Term Deposits Cash from Investment Activities	3.52	(180.31)	2,179.8
	H FLOWS FROM FINANCING ACTIVITIES		(2.10.05)	(240.0
	syment of Long Term Borrowings		(340.97)	(340.9
	eeds from Short Term Borrowings		(022.71)	(022.7
	syment of Short Term Borrowings		(932.71)	(932.7
	eeds from issuing shares			
	eeds from borrowings			
	syments of borrowings			
	dends paid	(0.01)	/A.W. W.C.	/07 /
	est paid	(0.01)	(27.56)	(1,301.3
Net (Cash from financial activities	(0.01)	(1,301.24)	(1,301.3
NET IN	NCREASE /(-) DECREASE IN CASH AND CASH EQUIVA	(41.21)	136.27	2,110.6
ODENI	ING BALANCE IN CASH AND CASH EQUIVALENTS	2,149.18	38.54	38.5
OPEN		6,177,10	D (24 p.) **	20.0

For, Gloval Longlife Hospital and Research Limited

GLODAK BOTTOLIFE ACTS TAL AND RESEARCH LIMITED

Regine Director, Sankarp Square, 3B, Beside Taj Skyline, Sindhu Bhavan Road, Antifiedabad — Blace: Ahmedabad O59, Gujarat Sindia CIN: L85110GJ2012PLC068700, Tel No.: (+91) 7211104280; Email:

- 1) The above Financial Results which are published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at its Meeting held on 12th November, 2025.
- 2) The statutory auditor has carried out a limited review of this financial results & expressed an unmodified review opinion.
- 3) The company operates in a single segment i.e. "Medical and Healthcare Services" and hence does not have any additional disclosures to be made under AS 17 Segment Reporting.
- 4) The accompanying financial results include the results for the half year ended March 31, 2025 being the balancing figure between the audited figures in respect of the full financial year and the unaudited year to date figures up to the first half year ended as on 30th September, 2024 of the previous financial year.
- 5) Previous period figures have been re-grouped / re-classified wherever necessary, to conform to current period's classification in order to comply with the requirements of the amended Schedule III to the Companies Act, 2013 effective 1st April 2021.
- 6) As the company is listed on SME Platform of BSE, it has been exempted from the applicability of IND-AS as per the proviso to rule 4 of companies (Indian Accounting Standards) Rules, 2015.
- 7) The Financial results have been prepared in accordance with the accounting standard as notified under section 133 of the Companies Act 2013 (Act), read with the relevant rules made thereunder and other accounting principles generally accepted in India.
- 8) The results for the half year ended 30th September, 2025 are available on the BSE Limited website (URL: www.bseindia.com) and also on the company's website (URL: www.globalhospital.co.in)
- 9) As the company do not have any Holding/Subsidiary/Joint Venture/Associate concern, no reporting has been made in this regards.